Oral Antidiabetic Drugs Market by Drugs Class Category (Sulfonylureas, Meglitinides, Biguanides and Alpha-glucosidase inhibitors) for Type 2 Diabetes mellitus  Analysis and Forecast, 2016 – 2022

Oral Antidiabetic Drugs Market by Drugs Class Category (Sulfonylureas, Meglitinides, Biguanides and Alpha-glucosidase inhibitors) for Type 2 Diabetes mellitus Analysis and Forecast, 2016 – 2022

Comments Off on Oral Antidiabetic Drugs Market by Drugs Class Category (Sulfonylureas, Meglitinides, Biguanides and Alpha-glucosidase inhibitors) for Type 2 Diabetes mellitus Analysis and Forecast, 2016 – 2022

According to the report, the global oral antidiabetic drug market accounted for USD 19.94 billion in 2016 and is expected to reach USD 35.91 billion by 2022, growing at a CAGR of around 10.2% between 2017 and 2022.Diabetes mellitus is a group of a metabolic disorder caused when the body is unable to produce required quantity of Insulin. Insulin is a hormone secreted by beta cells of the islet of Langerhans of the pancreas. Various symptoms associated with diabetes disorder include recurrent urination, increased thirst, and hunger. Diabetes can cause much chronic complication if left untreated. Some of them include acute complications like diabetic ketoacidosis, chronic kidney failure, foot ulcers, and damage to the eyes. Life-threatening disorders include necrosis, heart failure or death. According to WHO, in 2014 the number of people affected with diabetes are 422 million across the globe.

 

According to the report, the global oral antidiabetic drug market accounted for USD 19.94 billion in 2016 and is expected to reach USD 35.91 billion by 2022, growing at a CAGR of around 10.2% between 2017 and 2022.

Diabetes is a group of metabolic disorder characterized by the presence of high blood glucose level than normal level in an individual. The rise of blood glucose is due to inadequate insulin production, or because the body’s cells do not respond properly to insulin. Diabetes is broadly characterized into two types: Insulin-dependent diabetes mellitus (type 1) and Non-insulin dependent diabetes mellitus (type 2). Various initial symptoms associated with diabetes include increasing thirst, frequent urination, fatigue, weight and muscle loss, delayed wound healing and blurred vision.

The global rise in oral anti-diabetic drug market is mainly due to increase in the prevalence of diabetic patient across the globe. According to WHO, the number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014. This rise is continuously seen in developing countries like India and China. Moreover, the factors which are responsible for increasing numbers of the diabetic population globally include sedentary lifestyles, obesity, the rise in geriatric populations and poor healthcare services. However, a high cost of the drug is expected to restraint the growth of global oral anti-diabetic drug market. Nonetheless, huge market strength and untapped market of Asia Pacific and Africa market considered as a major opportunity for upcoming manufacturers of global oral anti-diabetic drug markets.

Global-Oral-Antidiabetic-Drug-Market

Based on the class of drug, the global oral anti-diabetic drug market is segmented into five types: sulfonylureas, meglitinides, biguanides, alpha-glucosidase inhibitors and others. Sulphonylureas segment of oral anti-diabetic drug market accounted for the largest market share in 2016 followed by biguanides derivatives. In 2016, Sulphonylureas accounted for about 37% share of the total oral anti-diabetic market. The growth is attributed due to the availability of low cost of drugs under this segment. A drug under this category includes glimepiride, gliclazide, glyburide and others. Whereas, Biguanides derivatives account for the second largest shares in the total oral anti-diabetic market followed by alpha-glucosidase inhibitors. Metformin is a biguanide class which is most preferred oral anti-diabetics drug currently prescribed by a physician for the treatment of Type 2 diabetes mellitus.

Key market players of oral anti-diabetic drug market include Eli Lilly, Abbott, Biocon, Sanofi, Sunpharma, Novartis, Novo Nordisk, Merck and Pfizer.

  • Chapter 1. Introduction
    • 1.1. Report Description And Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Global Oral Anti-Diabetic Market, 2016 – 2022 (USD Billion)
    • 2.2. Global Oral Anti-Diabetic Market: Snapshot
  • Chapter 3. Oral Anti-Diabetic – Market Dynamics
    • 3.1. Introduction
    • 3.2. Value Chain Analysis
    • 3.3. Market Drivers
      • 3.3.1. Global Oral Anti-Diabetic Market Drivers: Impact Analysis
      • 3.3.2. Rising Prevalence Of Diabetes Mellitus
      • 3.3.3. Increase In Obesity
    • 3.4. Market Restraints
      • 3.4.1. Global Oral Anti-Diabetic Market Restraints: Impact Analysis
      • 3.4.2. High Cost of Drugs
    • 3.5. Opportunities
      • 3.5.1. Market Strength
    • 3.6. Porter’s Five Forces Analysis
      • 3.6.1. Bargaining Power Of Suppliers
      • 3.6.2. Bargaining Power Of Buyers
      • 3.6.3. Threat From New Entrants
      • 3.6.4. Threat From New Substitutes
      • 3.6.5. Degree Of Competition
    • 3.7. Market Attractiveness Analysis
      • 3.7.1. Market Attractiveness Analysis, By Drug Class Segment
      • 3.7.2. Market Attractiveness Analysis, By Regional Segment
  • Chapter 4. Global Oral Anti-Diabetic Market – Competitive Landscape
    • 4.1. Company Market Share, 2016 (Subject To Data Availability)
    • 4.2. Strategic Development
      • 4.2.1. Acquisitions & Mergers
      • 4.2.2. New Type Launch
      • 4.2.3. Agreements, Partnerships, Collaborations And Joint Ventures
      • 4.2.4. Research And Development, Regional Expansion
    • 4.3. Type Portfolio
  • Chapter 5. Global Oral Anti-Diabetic Market – Drug Class Analysis
    • 5.1. Global Oral Anti-Diabetic Market: Drug Class Segment Overview
      • 5.1.1. Global Oral Anti-Diabetic Market Revenue Share, By Drug Class, 2016 And 2022
    • 5.2. Sulfonylureas
      • 5.2.1. Global Sulfonylureas Market, 2016 – 2022 (USD Billion)
      • 5.2.2. Glimepiride
        • 5.2.2.1. Glimepiride Oral Anti-Diabetic Market Revenue, 2016 – 2022 (USD Billion)
      • 5.2.3. Gliclazide
        • 5.2.3.1. Gliclazide Oral Anti-Diabetic Market Revenue, 2016 – 2022 (USD Billion)
      • 5.2.4. Glyburide
        • 5.2.4.1. Glyburide Oral Anti-Diabetic Market Revenue, 2016 – 2022 (USD Billion)
      • 5.2.5. Others
        • 5.2.5.1. Others Oral Anti-Diabetic Market Revenue, 2016 – 2022 (USD Billion)
    • 5.3. Meglitinides
      • 5.3.1. Global Meglitinides Market, 2016 – 2022 (USD Billion)
      • 5.3.2. Repaglinide
        • 5.3.2.1. Repaglinide Oral Anti-Diabetic Market Revenue, 2016 – 2022 (USD Billion)
      • 5.3.3. Nateglinide
        • 5.3.3.1. Nateglinide Oral Anti-Diabetic Market Revenue, 2016 – 2022 (USD Billion)
    • 5.4. Biguanides
      • 5.4.1. Global Biguanides Market, 2016 – 2022 (USD Billion)
      • 5.4.2. Metformin
        • 5.4.2.1. Metformin Oral Anti-Diabetic Market Revenue, 2016 – 2022 (USD Billion)
      • 5.4.3. Others
        • 5.4.3.1. Others Oral Anti-Diabetic Market Revenue, 2016 – 2022 (USD Billion)
      • 5.5. Alpha-glucosidase inhibitors
        • 5.5.1. Global Alpha-glucosidase inhibitors Market, 2016 – 2022 (USD Billion)
        • 5.5.2. Acarbose
          • 5.5.2.1. Acarbose Oral Anti-Diabetic Market Revenue, 2016 – 2022 (USD Billion)
        • 5.5.3. Voglibose
          • 5.5.3.1. Voglibose Oral Anti-Diabetic Market Revenue, 2016 – 2022 (USD Billion)
        • 5.5.4. Others
          • 5.5.4.1. Others Oral Anti-Diabetic Market Revenue, 2016 – 2022 (USD Billion)
  • Chapter 6. Global Oral Anti-Diabetic Market – Regional Segment Analysis
    • 6.1. Global Oral Anti-Diabetic Market: Regional Overview
      • 6.1.1. Global Oral Anti-Diabetic Market Revenue Share, By Region, 2016 And 2022
    • 6.2. North America
      • 6.2.1. North America Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022, (USD Billion)
      • 6.2.2. U.S.
        • 6.2.2.1. U.S. Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022 (USD Billion)
      • 6.2.3. Canada
        • 6.2.3.1. Canada Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022 (USD Billion)
    • 6.3. Europe
      • 6.3.1. Europe Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022 (USD Billion)
      • 6.3.2. Germany
        • 6.3.2.1. Germany Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022, (USD Billion)
      • 6.3.3. France
        • 6.3.3.1. France Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022, (USD Billion)
      • 6.3.4. U.K.
        • 6.3.4.1. U.K. Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022 (USD Billion)
    • 6.4. Asia Pacific
      • 6.4.1. Asia Pacific Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022 (USD Billion)
      • 6.4.2. China
        • 6.4.2.1. China Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022 (USD Billion)
      • 6.4.3. Japan
        • 6.4.3.1. Japan Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022 (USD Billion)
      • 6.4.4. India
        • 6.4.4.1. India Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022 (USD Billion)
    • 6.5. Latin America
      • 6.5.1. Latin America Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022 (USD Billion)
      • 6.5.2. Brazil
        • 6.5.2.1. Brazil Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022 (USD Billion)
    • 6.6. Middle East And Africa
      • 6.6.1. Middle East And Africa Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022 (USD Billion)
  • Chapter 7. Company Profile
    • 7.1. Abbott Laboratories
      • 7.1.1. Overview
      • 7.1.2. Financials
      • 7.1.3. Product Portfolio
      • 7.1.4. Business Strategy
      • 7.1.5. Recent Developments
    • 7.2. Biocon, Ltd
      • 7.2.1. Overview
      • 7.2.2. Financials
      • 7.2.3. Product Portfolio
      • 7.2.4. Business Strategy
      • 7.2.5. Recent Developments
    • 7.3. Eli Lilly and Company
      • 7.3.1. Overview
      • 7.3.2. Financials
      • 7.3.3. Product Portfolio
      • 7.3.4. Business Strategy
      • 7.3.5. Recent Developments
    • 7.4. Sun Pharma Industries, Ltd.
      • 7.4.1. Overview
      • 7.4.2. Financials
      • 7.4.3. Product Portfolio
      • 7.4.4. Business Strategy
      • 7.4.5. Recent Developments
    • 7.5. Novo Nordisk A/S
      • 7.5.1. Overview
      • 7.5.2. Financials
      • 7.5.3. Product Portfolio
      • 7.5.4. Business Strategy
      • 7.5.5. Recent Developments
    • 7.6. Pfizer
      • 7.6.1. Overview
      • 7.6.2. Financials
      • 7.6.3. Product Portfolio
      • 7.6.4. Business Strategy
      • 7.6.5. Recent Developments
    • 7.7. Sanofi
      • 7.7.1. Overview
      • 7.7.2. Financials
      • 7.7.3. Product Portfolio
      • 7.7.4. Business Strategy
      • 7.7.5. Recent Developments
    • 7.8. Novartis
      • 7.8.1. Overview
      • 7.8.2. Financials
      • 7.8.3. Product Portfolio
      • 7.8.4. Business Strategy
      • 7.8.5. Recent Developments
    • 7.9. Merck Group
      • 7.9.1. Overview
      • 7.9.2. Financials
      • 7.9.3. Product Portfolio
      • 7.9.4. Business Strategy
      • 7.9.5. Recent Development

List of Figures
?

1. Market Research Process
2. Market Research Methodology
3. Global Oral Anti-Diabetic  Market Revenue, 2016 – 2022 (USD Billion)
4. Porter’s Five Forces Analysis
5. Oral Anti-Diabetic: Market Attractiveness Analysis, By Drug Class Segment
6. Oral Anti-Diabetic: Market Attractiveness Analysis, By Regional Segment
7. Company Market Share Analysis, 2016 And 2022
8. Global Oral Anti-Diabetic Market Revenue Share By Drug Class, 2016 And 2022
9. Sulfonylureas Market, 2016 – 2022, (USD Billion)
10. Glimepiride Market, 2016 – 2022, (USD Billion)
11. Gliclazide Market, 2016 – 2022, (USD Billion)
12. Glyburide Market, 2016 – 2022, (USD Billion)
13. Others sulphonylureas Market, 2016 – 2022, (USD Billion)
14. Meglitinides Market, 2016 – 2022, (USD Billion)
15. Repaglinide Market, 2016 – 2022, (USD Billion)
16. Nateglinide Market, 2016 – 2022, (USD Billion)
17. Biguanides Market, 2016 – 2022, (USD Billion)
18. Metformin Market, 2016 – 2022, (USD Billion)
19. Others Market, 2016 – 2022, (USD Billion)
20. Alpha-glucosidase inhibitors Market, 2016 – 2022, (USD Billion)
21. Acarbose Market, 2016 – 2022, (USD Billion)
22. Voglibose Market, 2016 – 2022, (USD Billion)
23. Others Market, 2016 – 2022, (USD Billion)
24. Global Oral Anti-Diabetic Market Share, By Region, 2016 – 2022
25. North America Oral Anti-Diabetic Market, 2016 – 2022, (USD Billion)
26. U.S. Oral Anti-Diabetic Market, 2016 – 2022, (USD Billion)
27. Canada Oral Anti-Diabetic Market, 2016 – 2022, (USD Billion)
28. Europe Oral Anti-Diabetic Market, 2016 – 2022, (USD Billion)
29. Asia-Pacific Oral Anti-Diabetic Market, 2016 – 2022, (USD Billion)
30. China Oral Anti-Diabetic Market, 2016 – 2022, (USD Billion)
31. Japan Oral Anti-Diabetic Market, 2016 – 2022, (USD Billion)
32. India Oral Anti-Diabetic Market, 2016 – 2022, (USD Billion)
33. Latin America Oral Anti-Diabetic Market, 2016-2022, (USD Billion)
34. Brazil Oral Anti-Diabetic Market, 2016 – 2022, (USD Billion)
35. Middle East & Africa Oral Anti-Diabetic Market, 2016 – 2022, (USD Billion)


List of Tables

1. Oral Anti-Diabetic Market: Market Snapshot
2. Drivers Of Global Oral Anti-Diabetic Market: Impact Analysis
3. Restraints Of Global Oral Anti-Diabetic Market: Impact Analysis
4. North America Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022(USD Billion)
5. U.S. Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022(USD Billion)
6. Canada Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022(USD Billion)
7. Europe Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022(USD Billion)
8. U.K. Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022(USD Billion)
9. France Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022(USD Billion)
10. Germany Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022(USD Billion)
11. Asia-Pacific Oral Anti-Diabetic Market Revenue, By Drug Class 2016 – 2022(USD Billion)
12. Latin America Oral Anti-Diabetic Market Revenue, By Drug Class – 2022 (USD Billion)
13. Brazil Oral Anti-Diabetic Market Revenue, By Drug Class – 2022 (USD Billion)
14. The Middle East And Africa Oral Anti-Diabetic Market Revenue, By Drug Class – 2022 (USD Billion)

* Indicates required field.

Your Name*

Your Email*

Telephone Number*

Name of company*

Country Name*

How can we help you?

Prove You are Human*

captcha
Enter Capcha Image Properly



Share this Post

Related Posts

Checking...

Ouch! There was a server error.
Retry »

Sending message...

Enquiry Form

Fill in the form below and we will be in touch soon

Create Account



Log In Your Account